Back to Main

Faculty Detail    
Campus Address SC 650 Zip 0017
Phone  (205) 934-2334
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Neurology   Neurology Chair Office Assistant Professor
Center  Neurology   Alzheimer's Disease Center Assistant Professor
Center  Neurology   Evelyn F. McKnight Brain Institute Assistant Professor

Biographical Sketch 
Dr. Gerstenecker earned his PhD in clinical psychology from the University of Louisville in 2014, where he was awarded the John Richard Binford Memorial Award for excellence in scholarship and leadership, one of only two awards given to doctoral-level graduates, regardless of discipline. After graduating from UofL, Dr. Gerstenecker was awarded a fellowship in the Division of Neuropsychology, Department of Neurology, at UAB. He has since served as a faculty member in the Department of Neurology. In 2017, Dr. Gerstenecker received funding from the National Institutes of Health (NIH) to study the association between systemic inflammation, hippocampal subfield atrophy, and cognition in persons with multiple sclerosis (MS). In 2019, he was named the Early-Career Award recipient for the National Academy of Neuropsychology. Clinically, Dr. Gerstenecker specializes in the assessment of cognitive and functional ability in patients with suspected neurological compromise from a range of etiologies (e.g., neurodegenerative disorders, cancer, traumatic brain injury, cardiovascular disease, cerebrovascular disease).

Society Memberships
Organization Name Position Held Org Link
National Academy of Neuropsychology  Member - Membership Committee 

Research/Clinical Interest
Dr. Gerstenecker is currently the principle investigator (PI) for an NIH-funded K23 award focusing on the interaction between hippocampal atrophy, systemic inflammation, and cognition in persons with MS. Dr. Gerstenecker also has research interest in parkinsonism and the intersection of vascular risk and neurodegenerative disorders such as Alzheimer's disease. Dr. Gerstenecker has functioned as either primary investigator or coninvestigator on a number of funded projects in the areas of Parkinson's disease, Progressive Supranuclear Palsy, Alzheimer's disease, transcatheter aortic valve replacement (TAVR), and brain cancer.

Selected Publications 
Publication PUBMEDID
Gerstenecker, A., Roberson, E. D., Schellenberg, G. D., Standaert, D. G., Shprecher, D. R., Kluger, B. M., & Litvan, I. (Epub ahead of print). Genetic Influences on Cognition in Progressive Supranuclear Palsy. Movement Disorders. doi: 10.1002/mds.27196.

Gerstenecker, A. (2017). The Neuropsychology (Broadly Conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Archives of Clinical Neuropsychology, 32(7), 861-875.

Gerstenecker, A., Hoagey, D., Marson, D., & Kennedy, K. (2017). White Matter Degradation is Associated with Reduced Financial Capacity in Mild Cognitive Impairment and Alzheimer’s Disease. Journal of Alzheimer’s Disease, 60, 537-547.

Gerstenecker, A., Lowry, K., Myers, T., Bashir, K., Triebel, K., Martin, R., & Marson D. C. (2017). Medical Decision-Making Capacity and its Cognitive Predictors in Multiple Sclerosis: Preliminary Evidence. Journal of the Neurological Sciences, 380, 38-43.

Gerstenecker, A., Myers, T., Lowry, K., Martin, R., Triebel, K., Bashir, K., & Marson D. C. (epub ahead of
print). Financial Capacity and its Cognitive Predictors in Multiple Sclerosis. Archives of Clinical
Neuropsychology. DOI: 10.1093/arclin/acx039.

Vance, D. E., Frank, J. S., Bail, J., Deaver, J., Triebel, K. L., Niccolai, L. M., Gerstenecker, A.,
& Meneses, K. (epub ahead of print). Interventions for Cognitive Deficits in Breast Cancer Survivors Treated With Chemotherapy. Cancer Nursing. DOI: 10.1097/NCC.0000000000000349.

Niccolai, L. M., Triebel, K. L., Gerstenecker, A., McPherson, T. O., Cutter, C. R., Martin, R.
C., & Marson, D. C. (2017). Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment Due to Alzheimer’s Disease. Clinical Gerontologist, 40(1), 14-23.

Steward, K. A., Gerstenecker, A., Triebel, K. L., Kennedy, R. E., Novack, T., Dreer, L., &
Marson, D. C. (2016). 12-month recovery of medical decision-making capacity following traumatic brain injury. Neurology, 87, 1052-1059.

Gerstenecker, A., Triebel, K. L., Martin, R. C., Snyder, S., & Marson, D. C. (2016).
Both financial and cognitive decline predict clinical progression in MCI. Alzheimer’s
Disease and Associated Disorders, 30, 27-34.

Gerstenecker, A., Martin, R., Marson, D., & Triebel, K. (2016). Introducing
Demographic Corrections for the 10/36 Spatial Recall Test. International Journal of Geriatric Psychiatry, 31, 406-411.

Gerstenecker, A., Niccolai, L., Marson, D., & Triebel, K. (2016). Enhancing
Medical Decision-Making Evaluations: Introduction of Age-Corrected Normative Data for the Capacity to Consent to Treatment Instrument (CCTI). Assessment, 23, 232-239.

Gerstenecker, A., Eakin, A., Triebel, K., Martin, R., Swenson-Dravis, D., Petersen, R. C., &
Marson, D. (2016). Age and Education Corrected Older Adult Normative Data for a Short Form Version of the Financial Capacity Instrument. Psychological Assessment, 28, 737-749.

Gerstenecker, A., Duff, K., Meneses, K., Fiveash, J., Nabors, L. B., & Triebel, K. L. (2015).
Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. Journal of the International Neuropsychological Society, 21, 412-418.

Gerstenecker, A., Meneses, K., Duff, K., Fiveash, J., Marson, D., & Triebel, K. L. (2015).
Cognitive Predictors of Understanding Treatment Decisions in Patients with Newly Diagnosed Brain Metastases. Cancer, 121, 2013-2019.

Triebel, K. L., Gerstenecker, A., Marson, D., Fiveash, J. B., Meneses, K., Meyers, C. A., Cutter,
G., Martin, R. C., Watts, O., & Nabors, L. B. (2015). Capacity of patients with brain metastases to make treatment decisions. Psycho-Oncology, 24, 1448-1455.

Martin, R. C., Gerstenecker, A., Nabors, L. B., Marson, D. C., & Triebel, K. L. (2015). Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumors. Neuro-Oncology Practice, 2, 13-19.

Gerstenecker, A. & Mast, B. (2015). Mild Cognitive Impairment: A History and State of the
Current Diagnostic Criteria. International Psychogeriatrics, 27, 199-211.

Triebel, K. L., Gerstenecker, A., & Marson, D. C. (2014). Neuropsychological assessment of decisional capacity in an aging society. National Academy of Neuropsychology Bulletin, 28, 13-17.

Gerstenecker, A., Nabors, L. B., Meneses, K., Fiveash, J., Marson, D. C., Cutter, G., Martin, R.,
Meyers, C. A., & Triebel, K. L. (2014). Cognition in Patients with Newly Diagnosed Brain Metastasis: Profiles and Implications. Journal of Neuro-Oncology, 120, 179-185.

Gerstenecker, A., Mast, B., Shah, S., & Meeks, S. (2014). Tracking the cognition of
nursing home residents. Clinical Gerontologist, 37, 286-297.

Duff, K., Shprecher, D., Litvan, I., Gerstenecker, A., & Mast, B. (2014). Correcting for
demographic variables on the modified Telephone Interview for Cognitive Status. American Journal of Geriatric Psychiatry, 22, 1438-1443.

Gerstenecker, A., Duff, K., Mast, B., & Litvan, I., for the ENGENE-PSP Study Group. (2013).
Behavioral Abnormalities in Progressive Supranuclear Palsy. Psychiatry Research, 210, 1205-1210.

Duff, K., Gerstenecker, A., & Litvan, I., for the ENGENE-PSP Study Group. (2013). Functional
Impairment in Progressive Supranuclear Palsy. Neurology, 80, 380-384.

Gerstenecker, A., Mast, B., Duff, K., Ferman, T. J., & Litvan, I., for the ENGENE-PSP Study
Group. (2013). Executive Dysfunction is the Primary Cognitive Impairment in Progressive Supranuclear Palsy. Archives of Clinical Neuropsychology, 28, 104-113.

Marras, C., Armstrong, M. J., Meaney, C. A., Fox, S., Rothberg, B. Reginold, W. Tang-Wai, D. F., Gill, D., Eslinger, P. J., Zadikoff, C., Kennedy, N., Marshall, F. J., Mapstone, M., Chou, K. L., Persad, C., Litvan, I., Mast, B. T., Gerstenecker, A. T., Weintraub, S., Duff-Canning, S. (2013). Measuring Mild Cognitive Impairment in Patients with Parkinson’s disease. Movement Disorders, 28, 626-633.